Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion.

Tumor development and progression are strongly linked to inflammation and the presence of tumor-associated macrophages (TAMs). In murine tumors, antitumor activity can be achieved by targeting TAM recruitment, survival, activation, polarization, effector signaling, or extracellular matrix interactions. Thus, it may be possible to increase the efficacy of conventional cancer therapeutic strategies by targeting TAMs.